Nephron Sterile Compounding Center LLC is recalling 90,240 vials of Labetalol HCl and Neostigmine Methylsulfate injections due to potential cross-contamination during manufacturing. The recall affects 34,020 vials of Labetalol HCl (20 mg/4 mL) and 56,220 vials of Neostigmine Methylsulfate (3 mg/3 mL). The company initiated the recall after discovering manufacturing deviations that could allow product carry-over between different drug batches. No incidents or injuries have been reported to date. Hospitals and clinics should stop using these specific lots and contact the manufacturer for instructions.
The potential for cross-contamination means patients could receive unintended drug substances or impurities. This carry-over could cause unpredictable pharmacological reactions or interfere with the intended efficacy of the sterile injections.
Rx Only
Rx Only
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.